oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciencesoncotomsk-46Research ArticleЛАБОРАТОРНЫЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯLABORATORY AND EXPERIMENTAL STUDIESАнализ ассоциаций полиморфизма гена VEGF-A в позициях -2578A/C и +936C/T с разным рецепторным статусом у больных раком молочной железыANALYSIS OF ASSOCIATIONS OF VEGF-A GENE POLYMORPHISM AT POSITIONS 2578A/C AND +936C/T WITH DIFFERENT RECEPTOR STATUS IN BREAST CANCER PATIENTSШевченкоА. В.ShevchenkoA. V.shalla64@mail.ruКоненковВ. И.KonenkovV. I.БабышкинаН. Н.BabyshkinaN. N.nbabyshkina@mail.ruСавенковаО. В.SavenkovaO. V.СлонимскаяЕ. М.SlonimskayaE. M.ФГБУ «Научно-исследовательский институт клинической и экспериментальной лимфологии» СО РАМН, г. НовосибирскРоссияResearch Institute of Clinical and Experimental Lymphology, NovosibirskRussian FederationФГБУ «НИИ онкологии» СО РАМН, г. ТомскРоссияCancer Research Institute, SB RAMS, TomskRussian FederationФГБУ «НИИ онкологии» СО РАМН, г. Томск, ГБОУ ВПО «Сибирский государственный медицинский университет» Минздрава России, г. ТомскРоссияCancer Research Institute, SB RAMS, Tomsk, Siberian State Medical University, TomskRussian Federation20130902201601Сибирский онкологический журнал3237Copyright © Шевченко А.В., Коненков В.И., Бабышкина Н.Н., Савенкова О.В., Слонимская Е.М., 20162016Шевченко А.В., Коненков В.И., Бабышкина Н.Н., Савенкова О.В., Слонимская Е.М.Shevchenko A.V., Konenkov V.I., Babyshkina N.N., Savenkova O.V., Slonimskaya E.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/46

Проведено исследование функционального полиморфизма гена VEGF-A в позициях -2578 промоторного региона и +936 3`нетранслируемого региона у пациенток с раком молочной железы (РМЖ) с разным рецепторным статусом опухоли c целью выявления информативных маркеров, ассоциированных с риском развития заболевания. В анализ включены образцы ДНК 292 женщин с РМЖ. Генотипирование полиморфизмов С–2578A и C+936T VEG-FA осуществляли методом рестриктазного анализа продуктов амплификации (ПДРФ-анализ). Выявлены особенности распределения генотипов VEGF-A у пациенток с наличием эстрогеновых и прогестероновых рецепторов в опухолевых тканях и генотипы, ассоциированные с риском развития рецидивов РМЖ.

The study of functional polymorphism of the VEGF-A gene at positions –2578 in the promoter region and +936 in the 3`untranslated region in breast cancer patients with different receptor status of the tumor was undertaken to identify markers associated with risk of breast cancer. DNA samples from 292 women with breast cancer were analyzed. The genotyping of С–2578A and C+936T VEG-FA polymorphisms was performed using the method of restriction analysis of amplification products. The distributions of VEGF-A genotypes in patients having estrogen and progesterone receptors in tumor tissues were investigated and genotypes associated with risk of breast cancer recurrences were detected.

рак молочной железырецепторный статус опухолиполиморфизм VEGF-A генаbreast cancerreceptor status of the tumorVEGF-A gene polymorphismReferencesArias-Pulido H., Chaher N., Gong Y. et al. Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer // BMC Cancer. 2012. Vol. 12. P. 298.Arias-Pulido H., Chaher N., Gong Y. et al. Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer // BMC Cancer. 2012. Vol. 12. P. 298.Bando H., Weich H., Brokelmann M. et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer // Br. J. Cancer. 2005. Vol. 92. P. 553–561.Bando H., Weich H., Brokelmann M. et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer // Br. J. Cancer. 2005. Vol. 92. P. 553–561.Banyasz I., Szabo S., Bokodi G. et al. Genetic polymorphisms of vascular endothelial growth factor in severe preeclampsia // Mol. Hum. Reprod. 2006. Vol. 12. P. 233–236.Banyasz I., Szabo S., Bokodi G. et al. Genetic polymorphisms of vascular endothelial growth factor in severe preeclampsia // Mol. Hum. Reprod. 2006. Vol. 12. P. 233–236.Bland J., Altman D. Education and debate. The odds ratio // BMJ. 2000. Vol. 320. P. 1468.Bland J., Altman D. Education and debate. The odds ratio // BMJ. 2000. Vol. 320. P. 1468.Carmeliet P., Jain R. Angiogenesis in cancer and other diseases // Nature. 2000. Vol. 407. P. 249–257.Carmeliet P., Jain R. Angiogenesis in cancer and other diseases // Nature. 2000. Vol. 407. P. 249–257.Dabrosin C. Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo // Clin. Cancer Res. 2005. Vol. 11. P. 8036–8041.Dabrosin C. Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo // Clin. Cancer Res. 2005. Vol. 11. P. 8036–8041.Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer // Oncologist. 2000. Vol. 5. P. 37–44.Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer // Oncologist. 2000. Vol. 5. P. 37–44.Jakubowska A., Gronwald J., Menkiszak J. et al. The VEGF 936 C>T 3’UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women // Cancer Lett. 2007. Vol. 262 (1). P. 71–76.Jakubowska A., Gronwald J., Menkiszak J. et al. The VEGF 936 C>T 3’UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women // Cancer Lett. 2007. Vol. 262 (1). P. 71–76.Jin Q., Hemminki K., Enquist K. et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis // Clin. Cancer Res. 2005. Vol. 11. P. 3647–3653.Jin Q., Hemminki K., Enquist K. et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis // Clin. Cancer Res. 2005. Vol. 11. P. 3647–3653.Kataoka N., Cai Q., Wen W. et al. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women // Cancer Epidemiol. Biomarkers Prev. 2006. Vol. 15. P. 1148–1152.Kataoka N., Cai Q., Wen W. et al. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women // Cancer Epidemiol. Biomarkers Prev. 2006. Vol. 15. P. 1148–1152.Kidd L., Brock G., Vancleave T. et al. Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival // Cancer Caus. Contr. 2010. Vol. 21. P. 1545–1557.Kidd L., Brock G., Vancleave T. et al. Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival // Cancer Caus. Contr. 2010. Vol. 21. P. 1545–1557.Kim J., Oh D., Kwak S. et al. Genetic polymorphism of vascular endothelial growth factor (VEGF C936T) in the Korean population // Korean J. Biol. Sci. 2003. Vol. 7. P. 261–264.Kim J., Oh D., Kwak S. et al. Genetic polymorphism of vascular endothelial growth factor (VEGF C936T) in the Korean population // Korean J. Biol. Sci. 2003. Vol. 7. P. 261–264.Krippl P., Langsenlehner U., Renner W. et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk // Int. J. Cancer. 2003. Vol. 106. P. 468–471.Krippl P., Langsenlehner U., Renner W. et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk // Int. J. Cancer. 2003. Vol. 106. P. 468–471.Lambrechts D., Storkebaum E., Morimoto M. et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death // Nat. Genet. 2003. Vol. 34. P. 383–394.Lambrechts D., Storkebaum E., Morimoto M. et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death // Nat. Genet. 2003. Vol. 34. P. 383–394.Linardou H., Kalogeras K.T., Kronenwett R. et al. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of highrisk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial // Breast Cancer Res. 2012. Vol. 14. P. 145.Linardou H., Kalogeras K.T., Kronenwett R. et al. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of highrisk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial // Breast Cancer Res. 2012. Vol. 14. P. 145.Linderholm B.K., Lindh B., Beckman L. et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers // Clin. Breast Cancer. 2003. Vol. 4. P. 340–347.Linderholm B.K., Lindh B., Beckman L. et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers // Clin. Breast Cancer. 2003. Vol. 4. P. 340–347.Linderholm B., Lindh B., Tavelin B. et al. P53 and vascular-endothelialgrowth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma // Int. J. Cancer. 2000. Vol. 89. P. 51–62.Linderholm B., Lindh B., Tavelin B. et al. P53 and vascular-endothelialgrowth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma // Int. J. Cancer. 2000. Vol. 89. P. 51–62.Maae E., Andersen R., Steffensen K. et al. Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer // Anticancer Res. 2012. Vol. 32. P. 3619–3627.Maae E., Andersen R., Steffensen K. et al. Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer // Anticancer Res. 2012. Vol. 32. P. 3619–3627.Madeddy P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration // Exp. Physiol. 2004. Vol. 90 (3). P. 315–326.Madeddy P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration // Exp. Physiol. 2004. Vol. 90 (3). P. 315–326.Oliveira C., Lourenço G., Silva P. et al. Polymorphisms in the 5’- and 3’-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics // Tumour Biol. 2011. Vol. 32. P. 295–300.Oliveira C., Lourenço G., Silva P. et al. Polymorphisms in the 5’- and 3’-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics // Tumour Biol. 2011. Vol. 32. P. 295–300.Perrot-Applanat M., Di Benedetto M. Autocrine functions of VEGF in breast tumor cells: Adhesion, survival, migration and invasion // Cell Adh. Migr. 2012. Vol. 6. P. 547–553.Perrot-Applanat M., Di Benedetto M. Autocrine functions of VEGF in breast tumor cells: Adhesion, survival, migration and invasion // Cell Adh. Migr. 2012. Vol. 6. P. 547–553.Relf M., LeJeune S., Scott P. et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis // Cancer Res. 1997. Vol. 57. P. 963–969.Relf M., LeJeune S., Scott P. et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis // Cancer Res. 1997. Vol. 57. P. 963–969.Rodrigues P., Furriol J., Tormo E. et al. The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population // Breast Cancer Res. Treat. 2012. Vol. 133. P. 769–778.Rodrigues P., Furriol J., Tormo E. et al. The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population // Breast Cancer Res. Treat. 2012. Vol. 133. P. 769–778.Schneider B., Radovich M., Sledge G. et al. Association of polymorphismsSchneider B., Radovich M., Sledge G. et al. Association of polymorphismsof angiogenesis genes with breast cancer // Breast Cancer Res. Treat. 2008. Vol. 111. P. 157–163.of angiogenesis genes with breast cancer // Breast Cancer Res. Treat. 2008. Vol. 111. P. 157–163.Shahbazi M., Fryer A., Pravica V. et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection // J. Am. Soc. Nephrol. 2002. Vol. 13. P. 260–264.Shahbazi M., Fryer A., Pravica V. et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection // J. Am. Soc. Nephrol. 2002. Vol. 13. P. 260–264.Sheng Z., Guo-Ping W., Cong L., Muxiang Z. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis:prognostic markers for breast cancer // BMC Cancer. 2006. Vol. 6. P. 231–243.Sheng Z., Guo-Ping W., Cong L., Muxiang Z. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis:prognostic markers for breast cancer // BMC Cancer. 2006. Vol. 6. P. 231–243.Smith K., Bateman A., Fussell H. et al. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis // Eur. J. Immunogenet. 2004. Vol. 31. P. 167–173.Smith K., Bateman A., Fussell H. et al. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis // Eur. J. Immunogenet. 2004. Vol. 31. P. 167–173.

The authors declare that there are no conflicts of interest present.